Next Article in Journal
Stapled Peptides—A Useful Improvement for Peptide-Based Drugs
Previous Article in Journal
The Exchange Mechanism of Alkaline and Alkaline-Earth Ions in Zeolite N
Previous Article in Special Issue
Hydrophobic Interactions Drive Binding between Vascular Endothelial Growth Factor-A (VEGFA) and Polyphenolic Inhibitors
Open AccessArticle

Antiglycation Activity of Aucubin In Vitro and in Exogenous Methylglyoxal Injected Rats

1
Laboratory of Toxicology, Research Institute for Veterinary Science and College of Veterinary Medicine, Seoul National University, Seoul 08826, Korea
2
Department of Oral Pathology, School of Dentistry, Chonbuk National University, Jeonju 54896, Korea
*
Author to whom correspondence should be addressed.
Academic Editors: Chiara Tonelli and Katia Petroni
Molecules 2019, 24(20), 3653; https://doi.org/10.3390/molecules24203653
Received: 5 September 2019 / Revised: 30 September 2019 / Accepted: 8 October 2019 / Published: 10 October 2019
(This article belongs to the Special Issue Plant Bioactives in Preventing Chronic Diseases)
Advanced glycation end products (AGEs) is a causative factor of various chronic diseases, including chronic kidney disease and atherosclerosis. AGE inhibitors, such as aminoguanidine and pyridoxamine, have the therapeutic activities for reversing the increase in AGEs burden. This study evaluated the inhibitory effects of aucubin on the formation of methylglyoxal (MGO)-modified AGEs in vitro. We also determined the potential activity of aucubin in reducing the AGEs burden in the kidney, blood vessel, heart, and retina of exogenously MGO-injected rats. Aucubin inhibited the formation of MGO-modified AGE-bovine serum albumin (IC50 = 0.57 ± 0.04 mmol/L) and its cross-links to collagen (IC50 = 0.55 ± 0.02 mmol/L) in a dose-dependent manner. In addition, aucubin directly trapped MGO (IC50 = 0.22 ± 0.01 mmol/L) in vitro. In exogenous MGO-injected rats, aucubin suppressed the formation of circulating AGEs and its accumulation in various tissues. These activities of aucubin on the MGO-derived AGEs in vitro and in vivo showed its pharmacological potential for inhibiting AGEs-related various chronic diseases. View Full-Text
Keywords: advanced glycation end products; aucubin; methylglyoxal advanced glycation end products; aucubin; methylglyoxal
Show Figures

Figure 1

MDPI and ACS Style

Jung, E.; Park, S.-B.; Jung, W.K.; Kim, H.R.; Kim, J. Antiglycation Activity of Aucubin In Vitro and in Exogenous Methylglyoxal Injected Rats. Molecules 2019, 24, 3653.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop